Thelial Technologies
Lisbon
About Thelial Technologies
Thelial is a targeted carcinoma drug discovery and development company. theLiTE™ (Thelial – Live Targeted Epithelia) is our proprietary targeted carcinoma drug discovery platform technology; screening a library of more than 1200 drug candidates we have discovered six carcinoma targeted drug candidates, validating theLiTE™. To prove the concept we combine theLiTE™ with a powerful approach to advance novel therapies: drug repositioning, identifying new roles for known drug compounds. In parallel we develop a novel treatment class, targeting actin in cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $532.3K
- Funding stage: Seed
- Last round: Grant (Dec 2016)
- Website: thelial.com
- Phone: 351 91 770 8937
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/thelial-technologies-2239775 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.